Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bilateral uveal effusion and angle-closure glaucoma associated with bupropion use.

Archives of ophthalmology (Chicago, Ill. : 1960)·2012

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Angiogenesis: trabeculectomy and bevacizumab.

¹Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA.

Seminars in Ophthalmology

|April 18, 2009

Summary

Bevacizumab is a potential treatment for several eye conditions, including diabetic retinopathy and macular degeneration. Case reports suggest it may also enhance trabeculectomy surgery outcomes.

Area of Science:

Ophthalmology
Vascular Biology
Regenerative Medicine

Background:

Bevacizumab is an anti-VEGF antibody used to treat various neovascular eye diseases.
Proliferative diabetic retinopathy, neovascular glaucoma, and age-related macular degeneration are significant causes of vision loss.
Cystoid macular edema can also impair visual acuity.

Purpose of the Study:

To review the existing literature on bevacizumab's efficacy in treating specific neovascular eye conditions.
To evaluate bevacizumab's potential role as an adjunct therapy in glaucoma surgery.

Main Methods:

Literature review of published case reports and studies on bevacizumab in ophthalmology.
Analysis of treatment outcomes for conditions including proliferative diabetic retinopathy, neovascular glaucoma, AMD, and CME.

Related Experiment Videos

Last Updated: Jun 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Assessment of bevacizumab's impact when used alongside trabeculectomy.

Main Results:

Bevacizumab has demonstrated utility in managing proliferative diabetic retinopathy, neovascular glaucoma, neovascular AMD, and CME.
Published data indicates bevacizumab may offer benefits as an adjunctive treatment to trabeculectomy.

Conclusions:

Bevacizumab is a versatile therapeutic agent for multiple neovascular ocular conditions.
Evidence suggests bevacizumab can be a valuable addition to trabeculectomy, potentially improving surgical success rates.